Colorectal Cancer: Page 2

Biocartis, HiloProbe collaborating to commercialize, distribute colorectal cancer gene-expression test

By LabPulse.com staff writers

The test, ColoNode, is CE-marked and will be distributed first as a manual kit by Biocartis to expert laboratories in selected European countries.

May 9, 2023

Exact Sciences shares rise on 24% Q1 revenue growth, higher 2023 guidance

By Leo O'Connor

The firm is seeing a “dramatic increase in the electronic ordering rate” at health systems, which is helping grow sales, its CEO Kevin Conroy said.

May 10, 2023

Red flags signal early-onset colorectal cancer

By Elissa Wolfson

Recognizing four red flags for early-onset colorectal cancer may be key to earlier detection, diagnosis, and improved survival among younger patients.

May 5, 2023

Tempus granted FDA premarket approval for colorectal cancer CDx

By LabPulse.com staff writers

The NGS test detects substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status.

May 1, 2023

EarlySign colon cancer algorithm to be offered in Roche Navify suite of digital medical algorithms

By LabPulse.com staff writers

The addition of ColonFlag to the Navify suite is the latest development in an ongoing collaboration between EarlySign and Roche for early lung and gastric cancer detection.

May 1, 2023

Cancer patients’ molecular testing, treatment varies across oncology practices in study

By Elissa Wolfson

Access to molecular testing and targeted therapy for non-small cell lung cancer and colorectal cancer patients varies across oncology practices.

April 28, 2023

Mainz Biomed partners with Instituto de Microecologia for at-home CRC test distribution in Spain, Portugal

By LabPulse.com staff writers

The Instituto de Microecologia in Madrid will partner with Mainz to market the CRC detection test to physicians and their patients in the Iberian Peninsula.

April 26, 2023

Oncocyte announces results for gene expression test in colorectal cancer clinical trial

By LabPulse.com staff writers

The results, published in Clinical Cancer Research, show that DetermaIO identified more patients who were potentially responsive to immune checkpoint inhibitor treatment than current biomarkers identified.

April 10, 2023

BGI Genomics releases report on global patient awareness of colorectal cancer

By LabPulse.com staff writers

The responses highlight the need for more information about testing and greater access to affordable testing, and the critical role doctors play in offering information to patients in the need for screening for CRC, the third most common cancer worldwide.

April 7, 2023

Labcorp, Conference of National Black Churches to distribute screening kits for those at higher risk of colon cancer

By LabPulse.com staff writers

Under the partnership, the Conference of National Black Churches will distribute more than 3,000 colorectal screening test kits in several urban and rural locations including Atlanta, Dallas, Memphis, Washington, DC, New Haven, Los Angeles, and Richmond.

April 3, 2023

Targeted clinician intervention might improve follow-up colonoscopy rates: Exact Sciences funded study

By Elissa Wolfson

Reported follow-up colonoscopy rates within community settings are low, ranging from 18% to 75% within 12 months of a positive stool-based test result, failing to achieve the full benefits of widespread at-home screening.

January 18, 2023

At J.P. Morgan healthcare conference, Exact Sciences CEO describes pivotal meeting for Cologuard development

By Leo O'Connor

Kevin Conroy described a meeting in 2009 that changed everything for him as a business executive. Exact Sciences, without a proof of concept, was looking for a CEO to restart the company and develop a noninvasive colon cancer screening test.

January 10, 2023

Previous Page

Page 2 of 6

Next Page